<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30511687</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2542-5641</ISSN><JournalIssue CitedMedium="Internet"><Volume>131</Volume><Issue>23</Issue><PubDate><Year>2018</Year><Month>Dec</Month><Day>05</Day></PubDate></JournalIssue><Title>Chinese medical journal</Title><ISOAbbreviation>Chin Med J (Engl)</ISOAbbreviation></Journal><ArticleTitle>Association of <i>HLA-DR3</i> and <i>HLA-DR15</i> Polymorphisms with Risk of Systemic Lupus Erythematosus.</ArticleTitle><Pagination><StartPage>2844</StartPage><EndPage>2851</EndPage><MedlinePgn>2844-2851</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/0366-6999.246058</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Systemic lupus erythematosus (SLE) is an autoimmune disease under genetic control. Growing evidences support the genetic predisposition of HLA-DRB1 gene polymorphisms to SLE, yet the results are not often reproducible. The purpose of this study was to assess the association of two polymorphisms of HLA-DRB1 gene (HLA-DR3 and HLA-DR15) with the risk of SLE via a comprehensive meta-analysis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study complied with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Case-control studies on HLA-DRB1 and SLE were searched from PubMed, Elsevier Science, Springer Link, Medline, and Cochrane Library database as of June 2018. Analysis was based on the random-effects model using STATA software version 14.0.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 23 studies were retained for analysis, including 5261 cases and 9838 controls. Overall analysis revealed that HLA-DR3 and HLA-DR15 polymorphisms were associated with the significant risk of SLE (odds ratio [OR]: 1.60, 95% confidence interval (CI): 1.316-1.934, P = 0.129 and OR: 1.68, 95% CI: 1.334-2.112, P = 0.001, respectively). Subgroup analyses demonstrated that for both HLA-DR3 and HLA-DR15 polymorphisms, ethnicity was a possible source of heterogeneity. Specifically, HLA-DR3 polymorphism was not associated with SLE in White populations (OR: 1.60, 95% CI: 1.320-1.960, P = 0.522) and HLA-DR15 polymorphism in East Asian populations (OR: 1.65, 95% CI: 1.248-2.173, P = 0.001). In addition, source of control was another possible source for both HLA-DR3 and HLA-DR15 polymorphisms, with observable significance for HLA-DR3 in only population-based studies (OR: 1.65, 95% CI: 1.370-1.990, P = 0.244) and for HLA-DR15 in both population-based and hospital-based studies (OR: 1.38, 95% CI: 1.078-1.760, P = 0.123 and OR: 2.08, 95% CI: 1.738-2.490, P = 0.881, respectively).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">HLA-DRB1 gene may be a SLE-susceptibility gene, and it shows evident ethnic heterogeneity. Further prospective validations across multiple ethnical groups are warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Ke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Dermatology, China-Japan Friendship Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niu</LastName><ForeName>Wen-Quan</ForeName><Initials>WQ</Initials><AffiliationInfo><Affiliation>Institute of Clinical Medicine, China-Japan Friendship Hospital, Beijing 100029, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Dermatology, China-Japan Friendship Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Chin Med J (Engl)</MedlineTA><NlmUniqueID>7513795</NlmUniqueID><ISSNLinking>0366-6999</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059810">HLA-DR Serological Subtypes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C106559">HLA-DR15 antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015803">HLA-DR3 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059811">HLA-DRB1 Chains</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059810" MajorTopicYN="N">HLA-DR Serological Subtypes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015803" MajorTopicYN="N">HLA-DR3 Antigen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059811" MajorTopicYN="N">HLA-DRB1 Chains</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006239" MajorTopicYN="N">Haplotypes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="chi"><AbstractText><b>&#x7cfb;&#x7edf;&#x6027;&#x7ea2;&#x6591;&#x72fc;&#x75ae;</b><i><b>HLA-DR3</b></i><b>&#x548c;</b><i><b>HLA-DR15</b></i><b>&#x57fa;&#x56e0;&#x591a;&#x6001;&#x6027;</b><b>Meta</b><b>&#x5206;&#x6790;</b> <b>&#x6458;&#x8981;</b> <b>&#x80cc;&#x666f;&#xff1a;</b>&#x7cfb;&#x7edf;&#x6027;&#x7ea2;&#x6591;&#x72fc;&#x75ae;&#x662f;&#x4e00;&#x79cd;&#x9057;&#x4f20;&#x6027;&#x81ea;&#x8eab;&#x514d;&#x75ab;&#x75be;&#x75c5;&#xff0c;&#x7814;&#x7a76;&#x53d1;&#x73b0;&#x5176;&#x53d1;&#x75c5;&#x4e0e;<i>HLA-DRB1</i>&#x57fa;&#x56e0;&#x9057;&#x4f20;&#x591a;&#x6001;&#x6027;&#x76f8;&#x5173;&#x3002;&#x672c;&#x7814;&#x7a76;&#x65e8;&#x5728;&#x901a;&#x8fc7;&#x835f;&#x8403;&#x5206;&#x6790;&#x8bc4;&#x4f30;<i>HLA-DRB1</i>&#x57fa;&#x56e0;&#x7684;&#x4e24;&#x4e2a;&#x57fa;&#x56e0;&#x591a;&#x6001;&#x6027;&#xff08;<i>HLA-DR3</i>&#x548c;<i>HLA-DR15</i>&#xff09;&#x4e0e;SLE&#x98ce;&#x9669;&#x4e4b;&#x95f4;&#x7684;&#x5173;&#x7cfb;&#x3002; <b>&#x65b9;&#x6cd5;&#xff1a;</b>&#x672c;&#x7814;&#x7a76;&#x7b26;&#x5408;PRISMA&#x58f0;&#x660e;&#x3002;&#x4ece;PubMed&#xff0c;Elsevier Science&#xff0c;Springer Link&#xff0c;Medline&#x548c;Cochrane&#x56fe;&#x4e66;&#x9986;&#x6570;&#x636e;&#x5e93;&#x4e2d;&#x641c;&#x7d22;&#x4e86;&#x622a;&#x81f3;2018&#x5e74;6&#x6708;&#x5bf9;<i>HLA-DRB1</i>&#x548c;SLE&#x7684;&#x75c5;&#x4f8b;&#x5bf9;&#x7167;&#x7814;&#x7a76;&#x3002;&#x901a;&#x8fc7;STATA14.0&#x8f6f;&#x4ef6;&#x5efa;&#x7acb;&#x968f;&#x673a;&#x6548;&#x5e94;&#x6a21;&#x578b;&#x8fdb;&#x884c;&#x5206;&#x6790;&#x3002; <b>&#x7ed3;&#x679c;&#xff1a;</b>&#x672c;&#x6587;&#x5171;&#x7eb3;&#x5165;23&#x7bc7;&#x6587;&#x732e;&#x8fdb;&#x884c;&#x5206;&#x6790;&#xff0c;&#x5305;&#x62ec;5261&#x4f8b;&#x548c;9838&#x4f8b;&#x5bf9;&#x7167;&#x3002;&#x603b;&#x4f53;&#x5206;&#x6790;&#x663e;&#x793a;&#xff0c;<i>HLA-DR3</i>&#x548c;<i>HLA-DR15</i>&#x591a;&#x6001;&#x6027;&#x4e0e;SLE&#x7684;&#x663e;&#x7740;&#x98ce;&#x9669;&#x76f8;&#x5173;&#xff08;&#x4f18;&#x52bf;&#x6bd4;[<i>OR</i>]&#xff1a;1.595,95&#xff05;&#x7f6e;&#x4fe1;&#x533a;&#x95f4;&#xff08;<i>CI</i>&#xff09;&#xff1a;1.316-1.934&#xff0c;<i>P</i> &lt;0.01&#x548c;OR&#xff1a;1.678,95 &#xff05;<i>CI</i>&#xff1a;1.334-2.112&#xff0c;&#x5206;&#x522b;&#x4e3a;<i>P</i> &lt;0.001&#xff09;&#x3002;&#x4e9a;&#x7ec4;&#x5206;&#x6790;&#x8868;&#x660e;&#xff0c; <i>HLA-DR3</i>&#x548c;<i>HLA-DR15</i>&#x591a;&#x6001;&#x6027;&#xff0c;&#x79cd;&#x65cf;&#x662f;&#x5f02;&#x8d28;&#x6027;&#x7684;&#x53ef;&#x80fd;&#x6765;&#x6e90;&#x3002;&#x5177;&#x4f53;&#x800c;&#x8a00;&#xff0c;<i>HLA-DR3</i>&#x591a;&#x6001;&#x6027;&#x4e0e;&#x767d;&#x4eba;&#x7fa4;&#x4f53;&#x4e2d;&#x7684;SLE&#x663e;&#x8457;&#x76f8;&#x5173;&#xff08;<i>OR</i>&#xff1a;1.60,95&#xff05;<i>CI</i>&#xff1a;1.29-1.99&#xff0c;<i>P</i> &lt;0.01&#xff09;&#xff0c;&#x4ee5;&#x53ca;&#x4e1c;&#x4e9a;&#x4eba;&#x7fa4;&#x4e2d;&#x7684;<i>HLA-DR15</i>&#x591a;&#x6001;&#x6027;&#xff08;<i>OR</i>&#xff1a;1.646,95&#xff05;<i>CI</i>&#xff1a; 1.248-2.173&#xff0c;<i>P</i> &lt;0.01&#xff09;&#x3002;&#x6b64;&#x5916;&#xff0c;&#x60a3;&#x8005;&#x6765;&#x6e90;&#x662f;<i>HLA-DR3</i>&#x548c;<i>HLA-DR15</i>&#x5f02;&#x8d28;&#x6027;&#x7684;&#x53e6;&#x4e00;&#x4e2a;&#x53ef;&#x80fd;&#x6765;&#x6e90;&#xff0c;&#x793e;&#x533a;&#x6765;&#x6e90;&#x7684;&#x4eba;&#x7fa4;&#x5206;&#x6790;&#x7814;&#x7a76;&#x4e2d;&#x53ef;&#x53d1;&#x73b0;<i>HLA-DR3</i>&#x5f02;&#x8d28;&#x6027;&#x6709;&#x7edf;&#x8ba1;&#x5b66;&#x610f;&#x4e49;&#xff08;<i>OR</i>&#xff1a;1.65,95&#xff05;<i>CI</i>&#xff1a;1.37-1.99&#xff0c;<i>P</i> &lt;0.01&#xff09;&#x3002;&#x5728;<i>HLA-DR15</i>&#x793e;&#x533a;/&#x533b;&#x9662;&#x4eba;&#x7fa4;&#x6765;&#x6e90;&#x5206;&#x6790;&#x4e2d;&#xff0c;&#x540c;&#x6837;&#x5177;&#x6709;&#x7edf;&#x8ba1;&#x5b66;&#x610f;&#x4e49;&#xff08;<i>OR</i>&#xff1a;1.378,95&#xff05;<i>CI</i>&#xff1a;1.078-1.760&#xff0c;<i>P</i> &lt;0.01&#x548c;<i>OR</i>&#xff1a;2.08,95&#xff05;<i>CI</i>&#xff1a;1.738-2.49&#xff0c;<i>P</i> &lt;0.01&#xff09;&#x3002; <b>&#x7ed3;&#x8bba;</b><b>&#xff1a;</b> <i>HLA-DRB1</i>&#x57fa;&#x56e0;&#x53ef;&#x80fd;&#x662f;SLE&#x6613;&#x611f;&#x57fa;&#x56e0;&#xff0c;&#x5177;&#x6709;&#x79cd;&#x65cf;&#x5f02;&#x8d28;&#x6027;&#x3002;.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HLA-DR15</Keyword><Keyword MajorTopicYN="N">HLA-DR3</Keyword><Keyword MajorTopicYN="N">HLA-DRB1</Keyword><Keyword MajorTopicYN="N">Meta-Analysis</Keyword><Keyword MajorTopicYN="N">Systemic Lupus Erythematosus</Keyword></KeywordList><CoiStatement>There are no conflicts of interest</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>12</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30511687</ArticleId><ArticleId IdType="pmc">PMC6278195</ArticleId><ArticleId IdType="doi">10.4103/0366-6999.246058</ArticleId><ArticleId IdType="pii">ChinMedJ_2018_131_23_2844_246058</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Han EC. Systemic lupus erythematosus. N Engl J Med. 2012;366:573&#x2013;4. doi: 10.1056/NEJMc1115196.</Citation><ArticleIdList><ArticleId IdType="pubmed">22316462</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapoport M, Bloch O. Systemic lupus erythematosus. N Engl J Med. 2012;366:574. doi: 10.1056/NEJMc1115196.</Citation><ArticleIdList><ArticleId IdType="pubmed">22316463</ArticleId></ArticleIdList></Reference><Reference><Citation>Block SR, Winfield JB, Lockshin MD, D'Angelo WA, Christian CL. Studies of twins with systemic lupus erythematosus. A review of the literature and presentation of 12 additional sets. Am J Med. 1975;59:533&#x2013;52. doi: 10.1016/0002-9343(75)90277-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1101680</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentham J, Morris DL, Graham DS, Pinder CL, Tombleson P, Behrens TW, et al. Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. Nat Genet. 2015;47:1457&#x2013;64. doi: 10.1038/ng.3434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4668589</ArticleId><ArticleId IdType="pubmed">26502338</ArticleId></ArticleIdList></Reference><Reference><Citation>Gateva V, Sandling JK, Hom G, Taylor KE, Chung SA, Sun X, et al. Alarge-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet. 2009;41:1228&#x2013;33. doi: 10.1038/ng.468.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2925843</ArticleId><ArticleId IdType="pubmed">19838195</ArticleId></ArticleIdList></Reference><Reference><Citation>Han JW, Zheng HF, Cui Y, Sun LD, Ye DQ, Hu Z, et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet. 2009;41:1234&#x2013;7. doi: 10.1038/ng.472.</Citation><ArticleIdList><ArticleId IdType="pubmed">19838193</ArticleId></ArticleIdList></Reference><Reference><Citation>International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN) Harley JB, Alarc&#xf3;n-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet. 2008;40:204&#x2013;10. doi: 10.1038/ng.81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3712260</ArticleId><ArticleId IdType="pubmed">18204446</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito I, Kawasaki A, Ito S, Hayashi T, Goto D, Matsumoto I, et al. Replication of the association between the C8orf13-BLK region and systemic lupus erythematosus in a Japanese population. Arthritis Rheum. 2009;60:553&#x2013;8. doi: 10.1002/art.24246.</Citation><ArticleIdList><ArticleId IdType="pubmed">19180478</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris DL, Sheng Y, Zhang Y, Wang YF, Zhu Z, Tombleson P, et al. Genome-wide association meta-analysis in Chinese and European individuals identifies ten new loci associated with systemic lupus erythematosus. Nat Genet. 2016;48:940&#x2013;6. doi: 10.1038/ng.3603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4966635</ArticleId><ArticleId IdType="pubmed">27399966</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghodke-Puranik Y, Niewold TB. Immunogenetics of systemic lupus erythematosus: A comprehensive review. J Autoimmun. 2015;64:125&#x2013;36. doi: 10.1016/j.jaut.2015.08.004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4628859</ArticleId><ArticleId IdType="pubmed">26324017</ArticleId></ArticleIdList></Reference><Reference><Citation>Sestak AL, F&#xfc;rnrohr BG, Harley JB, Merrill JT, Namjou B. The genetics of systemic lupus erythematosus and implications for targeted therapy. Ann Rheum Dis. 2011;70(Suppl 1):i37&#x2013;43. doi: 10.1136/ard.2010.138057.</Citation><ArticleIdList><ArticleId IdType="pubmed">21339217</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong M, Tsao BP. Current topics in human SLE genetics. Springer Semin Immunopathol. 2006;28:97&#x2013;107. doi: 10.1007/s00281-006-0031-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16941108</ArticleId></ArticleIdList></Reference><Reference><Citation>Casta&#xf1;o-Rodr&#xed;guez N, Diaz-Gallo LM, Pineda-Tamayo R, Rojas-Villarraga A, Anaya JM. Meta-analysis of HLA-DRB1 and HLA-DQB1 polymorphisms in Latin American patients with systemic lupus erythematosus. Autoimmun Rev. 2008;7:322&#x2013;30. doi: 10.1016/j.autrev.2007.12.002.</Citation><ArticleIdList><ArticleId IdType="pubmed">18295738</ArticleId></ArticleIdList></Reference><Reference><Citation>Smikle M, Christian N, DeCeulaer K, Barton E, Roye-Green K, Dowe G, et al. HLA-DRB alleles and systemic lupus erythematosus in Jamaicans. South Med J. 2002;95:717&#x2013;9. doi: 10.1097/00007611-200295070-00011.</Citation><ArticleIdList><ArticleId IdType="pubmed">12144077</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerbase-Delima M, Pinto LC, Grumach A, Carneiro-Sampaio MM. HLA antigens and haplotypes in IgA-deficient Brazilian paediatric patients. Eur J Immunogenet. 1998;25:281&#x2013;5. doi: 10.1111/j.1399-0039.1988.tb01659.x.</Citation><ArticleIdList><ArticleId IdType="pubmed">9777327</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA statement. BMJ. 2009;339:b2535. doi: 10.1136/bmj.b2535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2714657</ArticleId><ArticleId IdType="pubmed">19622551</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain N, Jaffery G, Sabri AN, Hasnain S. HLA association in SLE patients from Lahore-Pakistan. Bosn J Basic Med Sci. 2011;11:20&#x2013;6. doi: 10.17305/bjbms.2011.2618.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4362559</ArticleId><ArticleId IdType="pubmed">21342137</ArticleId></ArticleIdList></Reference><Reference><Citation>Sirikong M, Tsuchiya N, Chandanayingyong D, Bejrachandra S, Suthipinittharm P, Luangtrakool K, et al. Association of HLA-DRB1*1502-DQB1*0501 haplotype with susceptibility to systemic lupus erythematosus in Thais. Tissue Antigens. 2002;59:113&#x2013;7. doi: 10.1034/j.1399-0039.2002.590206.x.</Citation><ArticleIdList><ArticleId IdType="pubmed">12028537</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadi W, Elhefny NE, Mahgoub EH, Almogren A, Hamam KD, Al-Hamed HA, et al. Relation between HLA typing and clinical presentations in systemic lupus erythematosus patients in Al-Qassim region, Saudi Arabia. Int J Health Sci (Qassim) 2014;8:159&#x2013;65. doi: 10.12816/0006082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4166988</ArticleId><ArticleId IdType="pubmed">25246883</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa H, Kawasaki A, Oka S, Ito I, Shimada K, Sugii S, et al. Human leukocyte antigens and systemic lupus erythematosus: A protective role for the HLA-DR6 alleles DRB1*13:02 and *14:03. PLoS One. 2014;9:e87792. doi: 10.1371/journal.pone.0087792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3912000</ArticleId><ArticleId IdType="pubmed">24498373</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K, Bang SY, Yoo DH, Cho SK, Choi CB, Sung YK, et al. Imputing variants in HLA-DR beta genes reveals that HLA-DRB1 is solely associated with rheumatoid arthritis and systemic lupus erythematosus. PLoS One. 2016;11:e0150283. doi: 10.1371/journal.pone.0150283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4769216</ArticleId><ArticleId IdType="pubmed">26919467</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HS, Chung YH, Kim TG, Kim TH, Jun JB, Jung S, et al. Independent association of HLA-DR and FCgamma receptor polymorphisms in Korean patients with systemic lupus erythematosus. Rheumatology (Oxford) 2003;42:1501&#x2013;7. doi: 10.1093/rheumatology/keg404.</Citation><ArticleIdList><ArticleId IdType="pubmed">12867584</ArticleId></ArticleIdList></Reference><Reference><Citation>Louthrenoo W, Kasitanon N, Wichainun R, Wangkaew S, Sukitawut W, Ohnogi Y, et al. The genetic contribution of HLA-DRB5*01:01 to systemic lupus erythematosus in Thailand. Int J Immunogenet. 2013;40:126&#x2013;30. doi: 10.1111/j.1744-313X.2012.01145.x.</Citation><ArticleIdList><ArticleId IdType="pubmed">22862923</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohd-Yusuf Y, Phipps ME, Chow SK, Yeap SS. HLA-A*11 and novel associations in Malays and Chinese with systemic lupus erythematosus. Immunol Lett. 2011;139:68&#x2013;72. doi: 10.1016/j.imlet.2011.05.001.</Citation><ArticleIdList><ArticleId IdType="pubmed">21658414</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan CF, Wu CJ, Chen HH, Dang CW, Chang FM, Liu HF, et al. Molecular analysis of HLA-DRB1 allelic associations with systemic lupus erythematous and lupus nephritis in Taiwan. Lupus. 2009;18:698&#x2013;704. doi: 10.1177/0961203308101955.</Citation><ArticleIdList><ArticleId IdType="pubmed">19502265</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimane K, Kochi Y, Suzuki A, Okada Y, Ishii T, Horita T, et al. An association analysis of HLA-DRB1 with systemic lupus erythematosus and rheumatoid arthritis in a Japanese population: Effects of *09:01 allele on disease phenotypes. Rheumatology (Oxford) 2013;52:1172&#x2013;82. doi: 10.1093/rheumatology/kes427.</Citation><ArticleIdList><ArticleId IdType="pubmed">23407388</ArticleId></ArticleIdList></Reference><Reference><Citation>Bettencourt A, Carvalho C, Leal B, Br&#xe1;s S, Lopes D, Martins da Silva A, et al. The protective role of HLA-DRB1(*) 13 in autoimmune diseases. J Immunol Res. 2015;2015:948723. doi: 10.1155/2015/</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4641944</ArticleId><ArticleId IdType="pubmed">26605347</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz GI, Shao X, Quach H, Ho KA, Sterba K, Noble JA, et al. Achild's HLA-DRB1 genotype increases maternal risk of systemic lupus erythematosus. J Autoimmun. 2016;74:201&#x2013;7. doi: 10.1016/j.jaut.2016.06.017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5079818</ArticleId><ArticleId IdType="pubmed">27388144</ArticleId></ArticleIdList></Reference><Reference><Citation>Piotrowski P, Wudarski M, Sowi&#x144;ska A, Olesi&#x144;ska M, Jagodzi&#x144;ski PP. TNF-308 G/A polymorphism and risk of systemic lupus erythematosus in the Polish population. Mod Rheumatol. 2015;25:719&#x2013;23. doi: 10.3109/14397595.2015.1008778.</Citation><ArticleIdList><ArticleId IdType="pubmed">25661739</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapitany A, Tarr T, Gyetvai A, Szodoray P, Tumpek J, Poor G, et al. Human leukocyte antigen-DRB1 and -DQB1 genotyping in lupus patients with and without antiphospholipid syndrome. Ann N Y Acad Sci. 2009;1173:545&#x2013;51. doi: 10.1111/j.1749-6632.2009.04642.x.</Citation><ArticleIdList><ArticleId IdType="pubmed">19758197</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinsson K, J&#xf3;nsd&#xf3;ttir S, Arason GJ, Kristj&#xe1;nsd&#xf3;ttir H, Fossdal R, Skaftad&#xf3;ttir I, et al. A study of the association of HLA DR, DQ, and complement C4 alleles with systemic lupus erythematosus in Iceland. Ann Rheum Dis. 1998;57:503&#x2013;5. doi: 10.1136/ard.57.8.503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1752717</ArticleId><ArticleId IdType="pubmed">9797559</ArticleId></ArticleIdList></Reference><Reference><Citation>de Holanda MI, Klumb E, Imada A, Lima LA, Alc&#xe2;ntara I, Greg&#xf3;rio F, et al. The prevalence of HLA alleles in a lupus nephritis population. Transpl Immunol. 2018;47:37&#x2013;43. doi: 10.1016/j.trim.2018.02.001.</Citation><ArticleIdList><ArticleId IdType="pubmed">29421495</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez-Tello A, Rodr&#xed;guez-Carre&#xf3;n AA, Jurado F, Yamamoto-Furusho JK, Castillo-V&#xe1;zquez M, Ch&#xe1;vez-Mu&#xf1;oz C, et al. Association of HLA-DRB1*16 with chronic discoid lupus erythematosus in MEXICAN mestizo patients. Clin Exp Dermatol. 2007;32:435&#x2013;8. doi: 10.1111/j.1365-2230.2007.02391.x.</Citation><ArticleIdList><ArticleId IdType="pubmed">17376212</ArticleId></ArticleIdList></Reference><Reference><Citation>McHugh NJ, Owen P, Cox B, Dunphy J, Welsh K. MHC class II, tumour necrosis factor alpha, and lymphotoxin alpha gene haplotype associations with serological subsets of systemic lupus erythematosus. Ann Rheum Dis. 2006;65:488&#x2013;94. doi: 10.1136/ard.2005.039842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1798099</ArticleId><ArticleId IdType="pubmed">16107511</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas-Alarc&#xf3;n G, Salgado N, Granados J, G&#xf3;mez-Casado E, Martinez-Laso J, Alcocer-Varela J, et al. Class II allele and haplotype frequencies in Mexican systemic lupus erythematosus patients: The relevance of considering homologous chromosomes in determining susceptibility. Hum Immunol. 2001;62:814&#x2013;20. doi: 10.1016/s0198-8859(01)00267-1.</Citation><ArticleIdList><ArticleId IdType="pubmed">11476905</ArticleId></ArticleIdList></Reference><Reference><Citation>Z&#xfa;&#xf1;iga J, Vargas-Alarc&#xf3;n G, Hern&#xe1;ndez-Pacheco G, Portal-Celhay C, Yamamoto-Furusho JK, Granados J. Tumor necrosis factor-alpha promoter polymorphisms in Mexican patients with systemic lupus erythematosus (SLE) Genes Immun. 2001;2:363&#x2013;6. doi: 10.1038/sj.gene.6363793.</Citation><ArticleIdList><ArticleId IdType="pubmed">11704801</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachicha H, Kammoun A, Mahfoudh N, Marzouk S, Feki S, Fakhfakh R, et al. Human leukocyte antigens-DRB1*03 is associated with systemic lupus erythematosus and anti-SSB production in South Tunisia. Int J Health Sci (Qassim) 2018;12:21&#x2013;7. doi: 10.1016/s0198-8859(01)00267-1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5870315</ArticleId><ArticleId IdType="pubmed">29623013</ArticleId></ArticleIdList></Reference><Reference><Citation>Reveille JD, Barger BO, Hodge TW. HLA-DR2-DRB1 allele frequencies in DR2-positive black Americans with and without systemic lupus erythematosus. Tissue Antigens. 1991;38:178&#x2013;80. doi: 10.1111/j.1399-0039.1991.tb01892.x.</Citation><ArticleIdList><ArticleId IdType="pubmed">1801308</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudwaleit M, Tikly M, Gibson K, Pile K, Wordsworth P. HLA class II antigens associated with systemic lupus erythematosus in black South Africans. Ann Rheum Dis. 1995;54:678&#x2013;80. doi: 10.1136/ard.54.8.678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1009967</ArticleId><ArticleId IdType="pubmed">7677446</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JY, Tian GH, Li YP, Wu TX, Bian ZX, Du L, et al. Systematic reviews/meta-analyses of integrative medicine in Chinese need regulation and monitoring urgently and some suggestions for its solutions. Chin J Integr Med. 2018;24:83&#x2013;6. doi: 10.1007/s11655-017-2427-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">29209960</ArticleId></ArticleIdList></Reference><Reference><Citation>Uman LS. Systematic reviews and meta-analyses. J Can Acad Child Adolesc Psychiatry. 2011;20:57&#x2013;9. doi: 10.1016/b978-0-12-415794-1.00013-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3024725</ArticleId><ArticleId IdType="pubmed">21286370</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshmukh US, Sim DL, Dai C, Kannapell CJ, Gaskin F, Rajagopalan G, et al. HLA-DR3 restricted T cell epitope mimicry in induction of autoimmune response to lupus-associated antigen Smd. J Autoimmun. 2011;37:254&#x2013;62. doi: 10.1016/j.jaut.2011.07.002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3372418</ArticleId><ArticleId IdType="pubmed">21868195</ArticleId></ArticleIdList></Reference><Reference><Citation>Migliorini P, Baldini C, Rocchi V, Bombardieri S. Anti-Sm and anti-RNP antibodies. Autoimmunity. 2005;38:47&#x2013;54. doi: 10.1080/08916930400022715.</Citation><ArticleIdList><ArticleId IdType="pubmed">15804705</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>